^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Foresight Solid Tumor Recurrence Test

Type:
Laboratory Developed Test
Related tests:

Details

Evidence
The assay is used to detect minimum residual disease (MRD) from the plasma of cancer patients using DNA sequencing. The test is custom designed for each patient to track phased variants identified from tumor tissue samples using whole genome sequencing. The test offers unprecedented sensitivity for MRD detection, enabling a limit of detection below one part per million.
Cancer:
Solid Tumor
Method:
PhasED-Seq technology